Jipan Xie

Vice President

Jipan Xie

New York

Education

Ph.D., health policy and administration, the University of North Carolina at Chapel Hill; M.D., Peking Union Medical College

Summary of Experience

Dr. Xie is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluations, health technology assessments in both the U.S. and global markets, and comparative outcomes research using clinical trial and real-world data. She has worked in a variety of disease areas, such as mental health, oncology, cardiovascular and other chronic diseases, as well as infectious diseases. Her work has been widely published in leading clinical, economic, and managed care journals, including Circulation, Stroke, PharmacoEconomics, Value in Health, and American Journal of Managed Care. Dr. Xie has extensive experience in emerging markets, particularly in China. Her work in this area includes outcomes research using high-quality EMR data, economic evaluations, market access of oncology drugs, burden of illness based on claims and surveys, and the China National Stroke Registry design and revision of the treatment guidelines for hypertension and diabetes. She was a coeditor of PharmacoEconomics journal's special issue on health care in China. She also serves as an adjunct professor at Shanghai Jiao Tong University School of Public Health. Prior to joining Analysis Group, Dr. Xie was a health service researcher at the Centers for Disease Control and Prevention, leading the health services and outcomes research in the Division for Heart Disease and Stroke Prevention.

Selected Publishing

  • Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension

    Curr Med Res Opin. 2014 Apr;30(4):637-43
    2014

    Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ

      View abstract
    Health Care
  • Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States

    J Med Econ. 2013; 16(2):278-88
    2013

    Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

      View abstract
    Health Care
  • A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy

    Eur J Gastroenterol Hepatol. 2013 Jun; 25(6):739-47
    2013

    Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

      View abstract
    Health Care
  • Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

    UroToday.com, Beyond the Abstract, July 2012
    2012

    Xie J

      View Article
    Health Care
  • Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

    Journal of Medical Economics; December 5, 2012 [Letter to the Editor]
    2012

    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M

      View abstract
    Health Care
  • Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer in the United States

    Journal of Medical Economics, 1-26, November 16, 2012
    2012

    Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M

      View abstract
    Health CareIntellectual PropertyStrategy, Policy & Analytics
  • Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents

    Pharmacoeconomics. 2012 Aug 1;30(8):e1-15
    2012

    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ

      View abstract
    Health CareStrategy, Policy & Analytics
  • Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

    J Med Econ. 2012; 15(6):1078-87
    2012

    Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

      View abstract
    Health Care
  • The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate-severe psoriasis

    JAAD. 2011 May 24
    2011

    Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM

      View abstract
    Health Care
  • Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

    Journal of Managed Care Pharmacy. 2011;17(8):621-34
    2011

    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW

      View article
    Health Care
  • Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement

    Curr Med Res Opin. 2010 Sep;26(9):2203-12
    2010

    Chang J, Yang W, Fellers T, Kahler K, Orloff J,  Xie J, Tsaneva M, Yu A,  Wu EQ

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram

    J Med Econ. 2010 Sep 29. [Epub ahead of print]
    2010

    Yu A,  Xie J, Bensimon A, Parikh K,  Wu E, Ben-Hamadi R, Blum S, Haim Erder

      View abstract
    Health Care
  • Systematic review: the costs of ulcerative colitis in Western countries

    Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
    2010

    Cohen R, Yu AP,  Wu EQXie J, Mulani P, Chao J

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Economic burden of psoriasis compared to the general population and stratified by disease severity

    Curr Med Res Opin. 2009 Oct;25(10):2429-38
    2009

    Yu AP, Tang J,  Xie JWu EQ, Gupta SR, Bao Y, Mulani PM

      View abstract
    Epidemiology & BiostatisticsHealth Care
  • Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States

    Stroke, 2006 Oct;37(10):2567-72
    2006

    Xie J, Wu E, Zheng Z, Croft J, Greenlund K, Mensah G, Labarthe D

      View abstract
    Epidemiology & BiostatisticsHealth Care
Jipan Xie
Practices